- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05544227
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Immunotherapy Regimen Given After Targeted Local Cryolysis (TLC) for Patients With Advanced/Metastatic Castration-resistant Prostate Cancer (mCRPC) OR Those With Metastatic Prostate Cancer Who Refused Hormone Therapy and Chemotherapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 11810
- Hospital Diomed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male >18 years old at the time of signed informed consent
- Provide written informed consent
- Subjects with advanced and/or metastatic histologically or cytologically confirmed castrate-resistant prostate cancer
- After failure after the receipt of previous treatment with one or more approved second-generation androgen-receptor-pathway inhibitors and with or without a prior course of taxanes therapy or those with metastatic prostate cancer who have refused hormone therapy and chemotherapy, or have not responded or progressed after standard therapies or for whom no further standard therapy exists or standard therapy is not available
- Patients who may or may not have had prior therapy with Lutetium Lu-177-PSMA-I&T
- Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v5 grade ≤ 1.
- Measurable disease by RECIST.
- Meet all eligibility criteria
- Able to undergo general anesthesia or conscious sedation
- Has undergone a cardiac work-up and received cardiac clearance two months before first treatment
- Has halted use of any anticoagulants or other blood thinners (including but not limited to heparin or warfarin) within five (5) days of each treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of < 3 (0, 1, or 2)
- All subjects with female partners of childbearing potential must use effective contraception throughout study treatment and for 120-150 days (4-5 months) after the last dose of study intervention
- Has at least one lesion within the prostate accessible transperineally using transrectal ultrasound (TRUS) that is demonstrable on PET/CT, CT, Ultrasound, or MRI and is accessible for infusion on TRUS or, if a radical prostatectomy has been performed, has a metastatic lesion or lymph node lesion that is demonstrable on PET/CT, CT, or MRI and accessible by a percutaneous needle to permit treatment.
- Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must be on stable doses for at least 42 days prior to the cryolysis
Adequate bone marrow, renal, and hepatic function, defined as follows:
a. Bone marrow function without transfusion 30 days before first dosing: i. Absolute neutrophil count ≥ 1.5 x 109/L; Lymphocyte count of ≥ 1.0 x 109/L; Platelet count ≥ 100 x 109/L; ii. Hemoglobin ≥ 9.0 g/dL b. Renal function" i. Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 or creatinine clearance calculated by Cockcroft-Gault equation ≥30 mL/ c. Hepatic function i. Alanine aminotransferase ≤ 3x upper limit of normal (ULN) ii. Aspartate aminotransferase ≤ 3x ULN iii. Total bilirubin ≤ ULN or total bilirubin ≤ 1.5x ULN with direct bilirubin ≤ ULN of the laboratory in subjects with documented Gilbert's Syndrome iv. Patients with liver metastases ≤5x ULN
- All clinically relevant toxicities related to prior anticancer therapy must have recovered to Grade ≤1 or baseline (except alopecia or ototoxicity
Exclusion Criteria:
- Has a known other primary malignancy other than prostate cancer that is progressing or has required active treatment in the last 3 years, excluding basal and squamous cell carcinoma, papillary thyroid cancer, and ductal carcinoma in situ of the breast
- Has an obstructed urinary system before or after stenting
- Has undergone major surgery, including local prostate intervention (excluding prostate biopsy), within 28 days prior to the first dose of study drug and has not recovered adequately from the toxicities and/or complications
- Has an active infection (including tuberculosis) requiring systemic therapy
- Has a history of non-infectious pneumonitis that required steroids
- Has received a live vaccine within 30 days prior to the enrollment Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days prior to the first treatment
- Significant cardiac or other medical illness such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia (e.g. New York Heart Association Class 4), or history of previous heart failure
- Malignant pleural effusions or ascites that require immediate intervention
- Prior history of autoimmune disease except hypothyroidism, uncontrolled or unmanaged diabetes, cardiac arrhythmia (unstable or untreated), hypersensitivity, or other illness or disease that in the opinion of the Principal Investigator, with consultation with Syncromune's Chief Medical Officer, makes the subject a poor candidate.
- Any primary or acquired immunodeficiency
- Active COVID infection or tests positive for COVID day before or day of planned treatment
- Known or suspected hepatitis B if active infection (subjects with chronic hepatitis B infection must have an undetectable Hepatitis B virus (HBV) viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion)
- Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load
- Any condition(s) that, in the opinion of the Investigator, would increase the risk for toxicities from study drug, interfere with subject compliance or conduct of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SV-102 Treatment Arm
|
SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Time Frame: Baseline through 30 days after end-of-treatment
|
Summary of treatment-emergent AEs, including NCI CTCAE v5.0 severity grade and relationship to either the device or study drugs.
|
Baseline through 30 days after end-of-treatment
|
Number of participants with deaths
Time Frame: Baseline through 30 days after end-of-treatment
|
Summary of deaths leading to study discontinuation
|
Baseline through 30 days after end-of-treatment
|
Number of participants with treatment-emergent SAEs and AEs
Time Frame: Baseline through 30 days after end-of-treatment
|
Summary of treatment-emergent SAEs, and AEs leading to study discontinuation
|
Baseline through 30 days after end-of-treatment
|
Assessment of laboratory values.
Time Frame: Baseline through 30 days after end-of-treatment
|
Summary of laboratory values over time and shifts in laboratory measurements by NCI CTCAE v5.0 grade.
|
Baseline through 30 days after end-of-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients in the Intent-to-Treat Population with complete response to SV-102.
Time Frame: Baseline through 12 weeks after end-of-treatment
|
Summary of objective response rate (ORR), presented as the percentage of patients with a complete response as assessed by the Investigator using PCWG3.
|
Baseline through 12 weeks after end-of-treatment
|
Number of patients in the Intent-to-Treat Population with complete response to SV-102.
Time Frame: Baseline through 12 weeks after end-of-treatment
|
Summary of objective response rate (ORR), presented as the percentage of patients with a complete response as assessed by the Investigator using RECIST 1.1.
|
Baseline through 12 weeks after end-of-treatment
|
Number of patients in the Intent-to-Treat Population with complete response to SV-102.
Time Frame: Baseline through 12 weeks after end-of-treatment
|
Summary of objective response rate (ORR), presented as the percentage of patients with a complete response as assessed by the Investigator using iRECIST.
|
Baseline through 12 weeks after end-of-treatment
|
Number of patients in the Intent-to-Treat Population with partial response to SV-102.
Time Frame: Baseline through 12 weeks after end-of-treatment
|
Summary of objective response rate (ORR), presented as the percentage of patients with a partial response as assessed by the Investigator using PCWG3.
|
Baseline through 12 weeks after end-of-treatment
|
Number of patients in the Intent-to-Treat Population with partial response to SV-102.
Time Frame: Baseline through 12 weeks after end-of-treatment
|
Summary of objective response rate (ORR), presented as the percentage of patients with a partial response as assessed by the Investigator using RECIST 1.1.
|
Baseline through 12 weeks after end-of-treatment
|
Number of patients in the Intent-to-Treat Population with partial response to SV-102.
Time Frame: Baseline through 12 weeks after end-of-treatment
|
Summary of objective response rate (ORR), presented as the percentage of patients with a partial response as assessed by the Investigator using iRECIST.
|
Baseline through 12 weeks after end-of-treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Carlos Vargas, MD, Williams Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Phase 1 SV-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on SV-102
-
Cosmo Technologies LtdCompletedInfectious Diarrhoea
-
Dartmouth-Hitchcock Medical CenterZimmer BiometCompletedKnee OsteoarthritisUnited States
-
ResMedMayo ClinicCompletedComplex Sleep Apnea SyndromeUnited States
-
AgNovos Healthcare, LLCRecruitingVertebral Fracture | Vertebral Compression Fracture | Vertebral CompressionGermany, Spain
-
Cosmo Technologies LtdCompletedDiarrhea-predominant Irritable Bowel SyndromeBelgium, Germany, Italy, Spain
-
RedHill Biopharma LimitedNot yet recruiting
-
Capso Vision, Inc.UnknownPatients Indicated for Periampullary or Pancreaticobiliary ExaminationUnited States
-
ResMedCRI-The Clinical Research Institute GmbHCompletedHeart Failure | Sleep Disordered BreathingGermany, Netherlands, Australia, Denmark, France, United Kingdom, Switzerland, Norway, Finland, Sweden, Czechia
-
Dr. Falk Pharma GmbHCompletedUncomplicated DiverticulitisGermany
-
Shanghai Eye Disease Prevention and Treatment CenterRecruiting